Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AGP concludes construction of new drug manufacturing facility in Ghana
AGP’s new manufacturing facility has been inspected by the Food and Drug Board of Ghana and issued required permits and approval for the importing of raw materials and
AGP’s new manufacturing facility has been inspected by the Food and Drug Board of Ghana and issued required permits and approval for the importing of raw materials and
Altravax is expected to use its proprietary MolecularBreeding directed evolution technology to create vaccines that provide protection against the various strains of HIV-1. Altravax has received exclusive rights
Loxonin gel 1% contains the same active ingredient, loxoprofen sodium hydrate as found in pills and powder formulations of the oral analgesic and anti-inflammatory Loxonin brand. Daiichi Sankyo
Accucaps said that the increase in growth of liquid filled soft gel formulated compounds is due to the increasing need to formulate high potency molecules that could not
Immunovaccine’s DepoVax platform is a lipid depot-based vaccine delivery technology. The primary cell-derived biologic, IRX-2, designed to restore the immune system, seeks to overcome cancer-induced immune suppression and
Strand claimed that Avadis NGS helps biologists visualise and perform downstream analysis on their NGS data, simply on a desktop computer. The introduction of sequencing technologies has resulted
SAFC’s 50,000 sqft cGMP fermentation expansion, which is expected to begin production in October 2010, will focus on niche fermentation of APIs and bulk drugs, producing secondary metabolites
As per the terms of the agreement, NovaBiotics is expected to expand its product portfolio by working with Isogenica on two research projects, one concerning peptide selection and
StemedicaAnC is expected to manufacture stem cells developed by Stemedica for the treatment of ischemic stroke and other degenerative disorders. Stemedica president and chief medical officer Nikolai Tankovich
Swedish Orphan Biovitrum chief scientific officer Peter Edman said that the orphan drug designation provides them with valuable regulatory support for the development of Sym001 in ITP that